Cancer stem cells equipped with powerful hedgehog signaling and better epigenetic memory: Avenues to look for cancer therapeutics.
Abstract Complex nature of the tumor is depicted at the cellular landscape by showing heterogeneity in the presence of cancer cells, cancer-associated stromal cells, mesenchymal stem cells and cancer stem cells (CSCs). One of the plausible view in cancer formation is suggested as the theory of cancer CSCs that is known as a source of initiation of tumorigenesis. In essence, these powerful CSCs are equipped with high sonic hedgehog (SHH) signaling and epigenetic memory power that support various tumor hallmarks. Truly, nature justifies its intent by limiting these stem cells with a potential to turn into CSCs and i...
Source: Current Cancer Drug Targets - August 8, 2019 Category: Cancer & Oncology Authors: Tandon I, Waghmode A, Sharma NK Tags: Curr Cancer Drug Targets Source Type: research

The role of large neutral amino acid transporter (LAT1) in cancer.
CONCLUSIONS: The increasing understanding of the role of LAT1 in cancer has led to an increase in interest surrounding its potential as a drug target for cancer treatment. PMID: 31376820 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 2, 2019 Category: Cancer & Oncology Authors: Lu X Tags: Curr Cancer Drug Targets Source Type: research

The role of Shcbp1 in signaling and disease.
Abstract Src homolog and collagen homolog (Shc) proteins have been identified as adapter proteins associated with cell surface receptors and shown to play important roles in signaling and disease. Shcbp1 acts as Shc SH2-domain binding protein 1 and is involved in the regulation of signaling pathways, such as FGF, NF-κB, MAPK/ERK, PI3K/AKT, TGF-β1/Smad and β-catenin signaling. Shcbp1 participates in T cell development, the regulation of downstream signal transduction pathways, and cytokinesis during mitosis and meiosis. In addition, Shcbp1 has been demonstrated to correlate with Burkitt-like lymphom...
Source: Current Cancer Drug Targets - June 20, 2019 Category: Cancer & Oncology Authors: Zhang GY, Ma ZJ, Wang L, Sun RF, Jiang XY, Yang XJ, Long B, Ye HL, Zhang SZ, Yu ZY, Shi WG, Jiao ZY Tags: Curr Cancer Drug Targets Source Type: research

Magnesium-dependent phosphatase (MDP) 1 is a potential suppressor of gastric cancer.
CONCLUSIONS: These results suggest that MDP1 protein suppresses the survival of gastric cancer cells and loss of MDP expression may benefit the recurrence of gastric cancer. PMID: 31218958 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 20, 2019 Category: Cancer & Oncology Authors: Zhu J, Deng L, Chen B, Huang W, Lin X, Chen G, Tzeng CM, Ying M, Lu Z Tags: Curr Cancer Drug Targets Source Type: research

Mogroside V Inhibits Hyperglycemia-induced Lung Cancer Cells Metastasis through Reversing EMT and Damaging Cytoskeleton.
CONCLUSION: These results suggest that mogroside V inhibits hyperglycemia-induced lung cancer cells migration and invasion through reversing EMT and damaging cytoskeleton. PMID: 31215378 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - June 19, 2019 Category: Cancer & Oncology Authors: Chen J, Jiao D, Li Y, Jiang C, Tang X, Song J, Chen Q Tags: Curr Cancer Drug Targets Source Type: research

Current Cancer Drug Development Strategies.
PMID: 30968768 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 12, 2019 Category: Cancer & Oncology Authors: Shao J, Gao Y Tags: Curr Cancer Drug Targets Source Type: research

HAMPT, A Novel Quadruple Drug Combination Designed for Cancer Metastatic Chemoprevention: From Hypothesis to Proof-of-concept.
CONCLUSION: The present study demonstrated that HAMPT is a novel quadruple drug combination that can safely and effectively prevent cancer metastasis. PMID: 30968769 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 12, 2019 Category: Cancer & Oncology Authors: Xu H, Wan L, Xu J, Liu J, Zheng N, Jia L Tags: Curr Cancer Drug Targets Source Type: research

Cytoprotective Agents to avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.
Abstract Anticancer agents play a vital role in the cure of patients suffering from malignancy. Though, the chemotherapeutic agents are associated with various adverse effects which produce significant toxic symptoms in the patients. But this therapy affects both the malignant and normal cells and leads to constricted therapeutic index of antimalignant drugs which adversely impacts the quality of patients' life. Due to these adversities, sufficient dose of drug is not delivered to patients leading to delay in treatment or improper treatment. Chemoprotective agents have been developed either to minimize or to mitig...
Source: Current Cancer Drug Targets - March 26, 2019 Category: Cancer & Oncology Authors: Rohilla S, Dureja H, Chawla V Tags: Curr Cancer Drug Targets Source Type: research

Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets.
CONCLUSION: These findings provide initial proof-of-concept data and rationale for further investigation of GDC-0980 in selected subgroups of pediatric leukemia patients. PMID: 30914027 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 26, 2019 Category: Cancer & Oncology Authors: Al-Ghabkari A, Perinpanayagam MA, Narendran A Tags: Curr Cancer Drug Targets Source Type: research

Mutational testing in gastrointestinal stromal tumor.
Abstract Targeted treatment has become a major modality in cancer management. Such cancer drugs are generally designed to treat tumors with certain genetic/genomic makeups. Mutational testing prior to prescribing targeted therapy is crucial in identifying who can receive clinical benefit from specific cancer drugs. Over the last two decades, gastrointestinal stromal tumors (GISTs) have evolved from histogenetically obscure to being identified as distinct gastrointestinal mesenchymal tumors with well-defined clinical and molecular characteristics, for which multiple lines of targeted therapies are available. Althou...
Source: Current Cancer Drug Targets - March 26, 2019 Category: Cancer & Oncology Authors: Wang Y, Call J Tags: Curr Cancer Drug Targets Source Type: research

Hepatocyte Growth Factor and Macrophage-Stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.
Hepatocyte Growth Factor and Macrophage-Stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer. Curr Cancer Drug Targets. 2019 Mar 26;: Authors: Wright JW, Church KJ, Harding JW Abstract Pancreatic cancer (PC) ranks twelfth in frequency of diagnosis but is the fourth leading cause of cancer related deaths with a 5 year survival rate of less than 7 percent. This poor prognosis occurs because the early stages of PC are often asymptomatic. Over-expression of several growth factors, most notably vascular endothelial growth factor (VEGF), has been implicated in PC resulting in dysfunction...
Source: Current Cancer Drug Targets - March 26, 2019 Category: Cancer & Oncology Authors: Wright JW, Church KJ, Harding JW Tags: Curr Cancer Drug Targets Source Type: research

Polyisoprenylated cysteinyl amide inhibitors deplete K-Ras and induce caspase-dependent apoptosis in lung cancer cells.
CONCLUSION: Taken together, PCAIs may be potentially useful as targeted therapies that suppress NSCLC progression through disruption of Ras-mediated growth signaling. PMID: 30914025 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 25, 2019 Category: Cancer & Oncology Authors: Nkembo AT, Amissah F, Ntantie E, Poku RA, Salako OO, Ikpatt OF, Lamango NS Tags: Curr Cancer Drug Targets Source Type: research

Advance In-silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors.
CONCLUSION: In the consequence in-silico based studies are considered to provide robustness towards a rational drug design and development approach hence to avoid the possibility of failures of drug candidates in the later stages of drug development phases. The results of this study smartly reveal the possible attributes of potent β-Glucuronidase inhibitors, for further experimental evaluation. PMID: 30894110 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - March 19, 2019 Category: Cancer & Oncology Authors: Yousuf M Tags: Curr Cancer Drug Targets Source Type: research

Anti-cancer effects of curcumin on myelodysplastic syndrome through the inhibition of enhancer of zeste homolog-2 (EZH2).
This study was designed to investigate the inhibitory effect and action mechanism of curcumin in myelodysplastic syndrome (MDS) in vitro and in vivo. Our results showed that curcumin can significantly suppress cell proliferation and induce cell apoptosis and cell cycle arrest in human MDS-derived cell lines. It reduced EZH2, DNA methyltransferase 3A(DNMT3a), ASXL1 and downstream H3K4me3, H3K27me3 and HOXA9 expression and inhibited EZH2 and H3K27me3 nuclear translocation. Curcumin also showed anti-cancer effects in a xenograft mouse model and reduced EZH2, H3K4me3 and H3K27me3 in vivo. EZH2 knockdown can reduce the H3K2...
Source: Current Cancer Drug Targets - February 12, 2019 Category: Cancer & Oncology Authors: Ma L, Zhang X, Wang Z, Huang L, Meng F, Hu L, Chen Y, Wei J Tags: Curr Cancer Drug Targets Source Type: research

An integrative "omics" approach, for identification of bona fides PLK1 associated biomarker in Oesophgeal adenocarcinoma.
CONCLUSION: Identification of a PLK1 dependent biosignature in OAC with high confidence in two omics levels proven the robustness and efficacy of our integrative approach. PMID: 30747067 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 10, 2019 Category: Cancer & Oncology Authors: Bibi N, Rashid S, Nicholson J, Malloy M, O'Neill R, Blake D, Hupp T Tags: Curr Cancer Drug Targets Source Type: research

Combinatorial inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant pheochromocytom.
CONCLUSIONS: Our results demonstrated that combinatorial inhibition of mTORC2 and Hsp90 could increase their antitumor effect and destabilize Akt signaling in PC12 cells, suggesting combinatorial inhibition of both mTORC2 and Hsp90 might be an effective therapeutic strategy for mPCC. PMID: 30727894 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 6, 2019 Category: Cancer & Oncology Authors: Zhang X, Gao F, Zhong S Tags: Curr Cancer Drug Targets Source Type: research

Autophagy And Apoptosis Specifc Knowledgebases-Guided Systems Pharmacology Drug Research.
CONCLUSION: The knowledgebases for apoptosis and autophagy and the integrated tools will accelerate our work in autophagy and apoptosis-related research and can be useful sources for information searching, target prediction, and new chemical discovery. PMID: 30727895 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - February 6, 2019 Category: Cancer & Oncology Authors: Fan P, Wang N, Wang L, Xie XQ Tags: Curr Cancer Drug Targets Source Type: research

The clinical prognostic value of LRG1 in esophageal squamous cell carcinoma.
Abstract BACKGROUND: Leucine-rich-alpha-2-glycoprotein1 (LRG1) is a new oncogene-related gene, which has been verified important to the development and poor prognosis of human cancers. However, whether it participates in esophageal squamous cell carcinoma (ESCC) progression remains unclear. OBJECTIVE: To investigate the expression level and functional influence of LRG1 in ESCC. METHOD: The expression of LRG1 was evaluated on the mRNA and protein level in ESCC patients. Then, correlation of LRG1 expression with clinicpathological variables was analyzed in ESCC. Besides, to clarify the biological function ...
Source: Current Cancer Drug Targets - February 3, 2019 Category: Cancer & Oncology Authors: Wang Y, Xing Q, Chen X, Wang J, Guan S, Chen X, Sun P, Wang M, Cheng Y Tags: Curr Cancer Drug Targets Source Type: research

Preface.
Abstract PMID: 30672408 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 25, 2019 Category: Cancer & Oncology Authors: Zhang R Tags: Curr Cancer Drug Targets Source Type: research

Targeted Nanotechnology from Bench to Bedside.
Abstract PMID: 30672409 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 25, 2019 Category: Cancer & Oncology Authors: Sapalidis K, Kosmidis C, Laskou S, Katsaounis A, Mantalobas S, Passos I, Michalopoulos N, Amaniti A, Sardeli C, Zarogoulidis P Tags: Curr Cancer Drug Targets Source Type: research

Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
CONCLUSION: This study demonstrates that ZA inhibits Rho-dependent amoeboid motility of PC3 cells, thus suggesting ZA as a potential therapy to impede the metastatic dissemination of PC3 cells. PMID: 30648509 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 15, 2019 Category: Cancer & Oncology Authors: Pietrovito L, Comito G, Parri M, Giannoni E, Chiarugi P, Taddei ML Tags: Curr Cancer Drug Targets Source Type: research

Isolation, solid-state structure determination, in silico and in vitro anticancer evaluation of an indole amino acid alkaloid L-Abrine †.
CONCLUSION: The solid-state zwitterion structure of the indole-containing alkaloid (α-methylamino-β-indolepropionic acid, L-abrine) has been confirmed for the first time by X-ray crystallography. Highly promising in silico and in vitro results indicate that L-abrine may find its space in future anticancer drug discovery research. PMID: 30636612 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 10, 2019 Category: Cancer & Oncology Authors: Laskar S, Espino O, Bandyopadhyay D Tags: Curr Cancer Drug Targets Source Type: research

Gefitinib represses JAK-STAT signaling activated by CRTC1-MAML2 fusion in mucoepidermoid carcinoma cells.
CONCLUSION: These findings provide new insights into the efficacy of gefitinib in treating mucoepidermoid carcinoma, and suggest that a combination of gefitinib and other inhibitors specifically against C1-M2 fusion could be more effective. PMID: 30605061 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 3, 2019 Category: Cancer & Oncology Authors: Wu Y, He Z, Li S, Tang H, Wang L, Yang S, Dong B, Qin J, Sun Y, Yu H, Zhang Y, Zhang Y, Guo Y, Wang Q Tags: Curr Cancer Drug Targets Source Type: research

EH-42, a novel small molecule induces apoptosis and inhibits migration and invasion of human hepatoma cells through suppressing STAT3 signaling pathway.
CONCLUSIONS: Taken together, these findings suggested that EH-42 could be a potential therapeutic agent for HCC treatment. PMID: 30585547 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 25, 2018 Category: Cancer & Oncology Authors: Gong QZ, Xiao D, Gong GY, Xu J, Wen XD, Feng F, Qu W Tags: Curr Cancer Drug Targets Source Type: research

Nanotherapy Targeting the Tumor Microenvironment.
Abstract Cancer is characterized by high mortality and low curability. Recent studies have shown that the mechanism of tumor resistance involves not only endogenous changes to tumor cells, but also to the tumor microenvironment (TME), which provides the necessary conditions for the growth, invasion, and metastasis of cancer cells, akin to Stephen Paget's hypothesis of "seed and soil." Hence, the TME is a significant target for cancer therapy via nanoparticles, which can carry different kinds of drugs targeting different types or stages of tumors. The key step of nanotherapy is the achievement of accurate...
Source: Current Cancer Drug Targets - December 19, 2018 Category: Cancer & Oncology Authors: Gong BS, Wang R, Xu HX, Miao MY, Yao ZZ Tags: Curr Cancer Drug Targets Source Type: research

Acknowledgements to Reviewers.
Authors: Abstract PMID: 30547738 [PubMed - in process] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 16, 2018 Category: Cancer & Oncology Tags: Curr Cancer Drug Targets Source Type: research

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Abstract Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, gefitinib, which was the first molecular targeted therapeutic agent, has actually doubled the survival time of NSCLC patients. Vigorous efforts of clinicians and researchers have revealed that lung cancer develops through the activating mutations of many driver genes including the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), v-...
Source: Current Cancer Drug Targets - December 9, 2018 Category: Cancer & Oncology Authors: Nagano T, Tachihara M, Nishimura Y Tags: Curr Cancer Drug Targets Source Type: research

Mesoporous silica nanoparticles as a prospective and promising approach for drug delivery and biomedical applications.
CONCLUSION: Through approaching to this review, the researchers can be aware of many new synthetic methods, smart designs proposed in recent year and remained question of MSNs at present. PMID: 30520373 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - December 5, 2018 Category: Cancer & Oncology Authors: Pu X, Li J, Qiao P, Li M, Wang H, Zong L, Yuan Q, Duan S Tags: Curr Cancer Drug Targets Source Type: research

Inhibition of the ATPase domain of human topoisomerase IIa on HepG2 cells by 1, 2-benzenedicarboxylic acid, mono (2-ethylhexyl) ester: molecular docking and dynamics simulations.
CONCLUSION: This study highlights our collaborative efforts to ascertain lead molecules from marine actinomycete. This is the first and foremost report to prove the mechanistic studies of the purified compound 1, 2-benzene dicarboxylic acid, mono(2-ethylhexyl) ester isolated from marine Streptomyces sp.VITJS4 against HepG2 cells. PMID: 30479215 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 27, 2018 Category: Cancer & Oncology Authors: Naine SJ, Devi CS, Doss CGP, Thirumal DK Tags: Curr Cancer Drug Targets Source Type: research

Insilico structure modeling and molecular docking analysis of phosphoribosyl pyrophosphate amidotransferase (PPAT) with antifolate inhibitors.
Abstract Cancer remains the one most serious disease worldwide. Robust metabolism is hallmark of the cancer. PPAT (phosphoribosyl pyrophosphate amidotransferase) catalyzes the first committed step of de novo purine biosynthesis. Hence PPAT, the key regulatory spot in De novo purine nucleotide biosynthesis is an attractive and credible drug target for leukemia and other cancer therapeutics. In the present study detailed computational analysis has been performed for PPAT protein the key enzyme in de novo purine biosynthesis is inhibited by many folate derivatives, hence we aimed to investigate and gauge the inhibito...
Source: Current Cancer Drug Targets - November 26, 2018 Category: Cancer & Oncology Authors: Bibi N, Parveen Z, Nawaz MS, Kamal MA Tags: Curr Cancer Drug Targets Source Type: research

Overexpression of Nemo-like kinase promotes the proliferation and invasion of lung cancer cells and indicates poor prognosis.
In conclusion, NLK is overexpressed in lung cancers and indicates poor prognosis. Overexpression of NLK activates the Wnt signaling pathway and EMT and promotes the proliferation and invasiveness of lung cancer cells. PMID: 30451112 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - November 19, 2018 Category: Cancer & Oncology Authors: Lei L, Wang Y, Zheng YW, Fei LR, Shen HY, Li ZH, Huang WJ, Yu JH, Xu HT Tags: Curr Cancer Drug Targets Source Type: research

Bone invasive properties of oral squamous cell carcinoma and its interactions with alveolar bone cells: an in vitro study.
Abstract BACKGROUND: Co-culture of cancer cells with alveolar bone cells could modulate bone invasion and destructions. However, the mechanisms of interaction between oral squamous cell carcinoma (OSCC) and bone cells remain unclear. OBJECTIVE: The aim of this study is to analyse the direct and indirect effects of OSCC cells in the stimulation of osteolytic activity and bone invasion. METHOD: Direct co-culture was achieved by culturing OSCC (TCA8113) with a primary alveolar bone cell line. In the indirect co-culture, the supernatant of TCA8113 cells was collected to culture the alveolar bone cells. To as...
Source: Current Cancer Drug Targets - November 2, 2018 Category: Cancer & Oncology Authors: Qallandar OB, Ebrahimi F, Islam F, Wahab R, Qiao B, Reher P, Gopalan V, Lam AK Tags: Curr Cancer Drug Targets Source Type: research

The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy.
Abstract The stability of mRNA is one of the key factors governing the regulation of eukaryotic gene expression and function. Human antigen R (HuR) is a RNA-binding protein that regulates the stability, translation, and nucleus-to-cytoplasm shuttling of its target mRNAs. While HuR is normally localized within the nucleus, it has been shown that HuR binds mRNAs in the nucleus and then escorts the mRNAs to the cytoplasm where HuR protects them from degradation. It contains several RNA recognition motifs, which specifically bind to adenylate and uridylate-rich regions within the 3'-untranslated region of the target m...
Source: Current Cancer Drug Targets - October 31, 2018 Category: Cancer & Oncology Authors: Wu M, Tong CWS, Yan W, To KKW, Cho WCS Tags: Curr Cancer Drug Targets Source Type: research

CT-707 Overcomes Resistance of crizotinib through activating PDPK1-AKT1 pathway by targeting FAK.
CONCLUSIONS: These findings indicate that CT-707 may be a promising therapeutic agent against crizotinib-resistance in NSCLC. PMID: 30381078 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 31, 2018 Category: Cancer & Oncology Authors: Liang C, Zhang N, Tan Q, Liu S, Luo R, Wang Y, Shi Y, Han X Tags: Curr Cancer Drug Targets Source Type: research

Characterization of YY1 OPB Peptide for Its Anticancer Activity.
Abstract The oncoprotein binding (OPB) domain of Yin Yang 1 (YY1) consists of 26 amino acids between G201 and S226, and is involved in YY1 interaction with multiple oncogene products, including MDM2, AKT, EZH2 and E1A. Through the OPB domain, YY1 promotes the oncogenic or proliferative regulation of these oncoproteins in cancer cells. We previously demonstrated that a peptide with the OPB sequence blocked YY1-AKT interaction and inhibited breast cancer cell proliferation. In the current study, we characterized the OPB domain and determined a minimal region for peptide design to suppress cancer cells. Using alanine...
Source: Current Cancer Drug Targets - October 31, 2018 Category: Cancer & Oncology Authors: Qi Y, Yan T, Chen L, Zhang Q, Wang W, Han X, Li D, Shi J, Sui G Tags: Curr Cancer Drug Targets Source Type: research

HSF1 as a Cancer Biomarker and Therapeutic Target.
Abstract Heat shock factor 1 (HSF1) was discovered in 1984 as the master regulator of the heat shock response. In this classical role, HSF1 is activated following cellular stresses such as heat shock that ultimately lead to HSF1-mediated expression of heat shock proteins to protect the proteome and survive these acute stresses. However, it is now becoming clear that HSF1 also plays a significant role in several diseases, perhaps none more prominent than cancer. HSF1 appears to have a pleiotropic role in cancer by supporting multiple facets of malignancy including migration, invasion, proliferation, and cancer cell...
Source: Current Cancer Drug Targets - October 18, 2018 Category: Cancer & Oncology Authors: Carpenter RL, Gokmen-Polar Y Tags: Curr Cancer Drug Targets Source Type: research

Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors.
CONCLUSION: We conclude that brain tumorigenesis was related to oxidative stress and changes in brain enzyme and non-enzyme antioxidant defense systems with gender differences, whereas plasma did not reflect the main redox changes that occur at brain level. PMID: 30338739 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 18, 2018 Category: Cancer & Oncology Authors: Ramírez-Expósito MJ, Mayas MD, Carrera-González MP, Martínez-Martos JM Tags: Curr Cancer Drug Targets Source Type: research

Osimertinib quantitative and gene variation analyses in cerebrospinal fluid and plasma of non-small cell lung cancer patient with leptomeningeal metastases.
CONCLUSIONS: ctDNA from CSF might be a useful biomarker for monitoring the efficacy of treatment and an effective complement to nuclear magnetic resonance (MRI) for LM. PMID: 30332963 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 17, 2018 Category: Cancer & Oncology Authors: Song Y, Liu P, Huang Y, Guan Y, Han X, Shi Y Tags: Curr Cancer Drug Targets Source Type: research

Gene Therapy and Photothermal Therapy of Layer-by-Layer Assembled AuNCs /PEI/miRNA/ HA Nanocomplexes.
Abstract MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. In this research, we successfully constructed 11-mercaptoundecanoic acid modified gold nanocages (AuNCs)/polyethyleneimine (PEI)/miRNA/hyaluronic acid (HA) complexes (abbreviated as AuNCs/PEI/miRNA/HA) using a layer-by-layer method for target-specific intracellular delivery of miRNA by HA receptor mediated endocytosis. The results of UV spectra, hydrodynamic diameter and zeta potential analyse...
Source: Current Cancer Drug Targets - October 16, 2018 Category: Cancer & Oncology Authors: Yan LJ, Guo XH, Wang WP, Hu YR, Duan SF, Liu Y, Sun Z, Huang SN, Li HL Tags: Curr Cancer Drug Targets Source Type: research

Ursolic acid in cancer treatment and metastatic chemoprevention: from synthesized derivatives to nanoformulations in preclinical studies.
CONCLUSION: The information presented in this article can provide useful references for further studies on making UA a promising anti-cancer drug, especially as a prophylactic metastatic agent for clinical applications. PMID: 30332961 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 16, 2018 Category: Cancer & Oncology Authors: Zou J, Lin J, Li C, Zhao R, Fan L, Yu J, Shao J Tags: Curr Cancer Drug Targets Source Type: research

Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles.
CONCLUSION: NPs can improve the anti-inflammation activity of CUR by enhancing the drug release and cellular uptake efficiency compared to MPs. Thus, it is a promising and a readily scalable drug vehicle for efficient clinical treatment of UC. PMID: 30332962 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 16, 2018 Category: Cancer & Oncology Authors: Ma P, Si X, Chen Q, Ma L, Hou M, Xu Z, Kang Y, Wang J, Xiao B Tags: Curr Cancer Drug Targets Source Type: research

The Multifunctional Protein p62 and Its Mechanistic Roles in Cancers.
Abstract The multifunctional signaling hub p62 is well recognized as ubiquitin sensor and selective autophagy adaptor under myriad stress conditions including cancer. As a ubiquitin sensor, p62 promotes NFκB activation by facilitating TRAF6 ubiquitination and aggregation. As a selective autophagy receptor, p62 links ubiquitinated substrates including p62 itself for lysosome-mediated degradation. p62 plays crucial roles in myriad cellular processes including DNA damage response, aging/senescence, infection and immunity, chronic inflammation, and cancerogenesis, dependent on or independent of autophagy. Target...
Source: Current Cancer Drug Targets - October 16, 2018 Category: Cancer & Oncology Authors: Ning S, Wang L Tags: Curr Cancer Drug Targets Source Type: research

Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells.
CONCLUSION: Our results suggest that the small molecule inhibitors of STAT3 upstream kinases, ruxolitinib, tofactinib, KX2-391, and dasatinib could be novel and attractive candidate drugs for the treatments of human medulloblastoma. PMID: 30332965 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 16, 2018 Category: Cancer & Oncology Authors: Wei J, Ma L, Li C, Pierson CR, Finlay JL, Lin J Tags: Curr Cancer Drug Targets Source Type: research

Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.
Abstract Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, survival has improved little over the last 20 years. The management of patients with ovarian cancer also remains similar despite studies showing striking differences and heterogeneity among different subtypes. It is therefore clear that novel targeted therapeutics are urgently needed to impro...
Source: Current Cancer Drug Targets - October 9, 2018 Category: Cancer & Oncology Authors: Liang Z, Lu Z, Zhang Y, Shang D, Li R, Liu L, Zhao Z, Zhang P, Lin Q, Feng C, Zhang Y, Liu P, Tu Z, Liu H Tags: Curr Cancer Drug Targets Source Type: research

The association of neuronal stress with activating transcription factor 3 in dorsal root ganglion of in vivo and in vitro models of bortezomib-induced neuropathy.
This study exhibited important mechanistic insight into how BTZ induces neurotoxicity through the activation of ATF3 resulting in intracellular oxidative stress, mitochondrial dysfunction, cell apoptosis, and ER stress and provided a novel potential therapeutic target by blocking ATF3 signaling. PMID: 30289077 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - October 3, 2018 Category: Cancer & Oncology Authors: Yin Y, Qi X, Qiao Y, Liu H, Yan Z, Li H, Liu Z Tags: Curr Cancer Drug Targets Source Type: research

In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells.
CONCLUSION: Our result demonstrated the in vitro and in vivo antimetastatic effect of pan-PI3K inhibitor ZSTK474 on prostate cancer DU145 cells, suggesting the potential application in prostate cancer patients. PMID: 30205797 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - September 10, 2018 Category: Cancer & Oncology Authors: Liu J, Tan X, Zhao W, Liu J, Xing X, Fan G, Zhang P, Zhang Z, Zhong Y, Kong D Tags: Curr Cancer Drug Targets Source Type: research

c-Myc inhibitor 10074-G5 induces murine and human hematopoietic stem and progenitor cell expansion and HDR modulator Rad51 expression.
Abstract c-Myc plays a major role in the maintenance of glycolytic metabolism and hematopoietic stem cell (HSC) quiescence. Targeting modulators of HSC quiescence and metabolism could lead to HSC cell cycle entry with concomitant expansion. Here we show that c-Myc inhibitor 10074-G5 treatment leads to 2-fold increase in murine LSKCD34low HSC compartment post 7 days. In addition, c-Myc inhibition increases CD34+ and CD133+ human HSC number. c-Myc inhibition leads to downregulation of glycolytic and cyclin-dependent kinase inhibitor (CDKI) gene expression ex vivo and in vivo. In addition, c-Myc inhibition upregulate...
Source: Current Cancer Drug Targets - September 4, 2018 Category: Cancer & Oncology Authors: Aksoz M, Albayrak E, Aslan GS, Turan RD, Alyazici LY, Siyah P, Tusuz EC, Canikyan S, Yucel D, Meric N, Gulbas Z, Sahin F, Kocabas F Tags: Curr Cancer Drug Targets Source Type: research

Cordycepin downregulates Cdk-2 to interfere with cell cycle and increases apoptosis by generating ROS in cervical cancer cells: in vitro and in silico study.
In this study, we investigated cordycepin effect on cervical cancer cells in vitro. Results indicate that treatment of cordycepin controlled SiHa and Hela cervical cancer cell growth, increased the rate of their apoptosis, and interfered with cell cycle, specifically elongated S-phase. By using qPCR, we investigated the expression of anti-apoptotic and pro-apoptotic proteins as well as cell cycle protein's expression in mRNA levels, and found there was a downregulation of cell cycle proteins CDK-2, CYCLIN-A2 and CYCLIN-E1 by cordycepin treatment but no significant change in pro-apoptotic or anti-apoptotic proteins. The int...
Source: Current Cancer Drug Targets - September 4, 2018 Category: Cancer & Oncology Authors: Tania M, Shawon J, Saif K, Kiefer R, Khorram MS, Halim MA, Khan MA Tags: Curr Cancer Drug Targets Source Type: research

Cathepsin L induces proangiogenic changes in human omental microvascular endothelial cells via activation of the ERK1/2 pathway.
CONCLUSION: These data suggest that CathL acts as an extracellular ligand and plays an important pro-angiogenic, and thus pro-metastatic, role during EOC metastasis to the omentum, by activating the omental microvasculature, and thus can potentially be targeted therapeutically in the future. PMID: 30173647 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 31, 2018 Category: Cancer & Oncology Authors: Pranjol MZI, Gutowski NJ, Hannemann M, Whatmore JL Tags: Curr Cancer Drug Targets Source Type: research

The evaluation of animal models in the development of anticancer agents : from preclinical to clinical tests.
CONCLUSION: these information helps smart select the suitable predictive model for anti-cancer drugs with the different mechanisms and emphasized the pharmaceutical challenges behind and ahead. PMID: 30117392 [PubMed - as supplied by publisher] (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - August 16, 2018 Category: Cancer & Oncology Authors: Wang J, Dong H, Peng H, Liu J, Zheng N, Xie X, Jia L Tags: Curr Cancer Drug Targets Source Type: research